Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics (CLDX)
:CLDX
CLDX Stock Chart & Stats
$26.83
-$0.90(-3.26%)
At close: 4:00 PM EST
$26.83
-$0.90(-3.26%)
Day’s Range― - ―
52-Week Range$14.40 - $29.38
Previous CloseN/A
Volume733.18K
Average Volume (3M)1.15M
Market Cap
$1.76B
Enterprise Value$729.97M
Total Cash (Recent Filing)$630.34M
Total Debt (Recent Filing)$3.03M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 05, 2025EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding66,406,550
10 Day Avg. Volume941,780
30 Day Avg. Volume1,147,455
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue126.05
Enterprise Value/Gross Profit146.82
Enterprise Value/Ebitda-3.15
Forecast
1Y Price Target
$49.33Price Target Upside83.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyBarzo provides a unique means of treating chronic spontaneous urticaria (CSU) with a well-studied and established mechanism of action, translating to compelling efficacy in clinical trials.
Market PositionBarzo's capacity to control and treat angioedema in CSU patients adds to its potential market value.
Regulatory PotentialBarzo's success could help identify the caliber of efficacy and safety data sought for potential approval in the treatment of CSU.
Bears Say
Limited Treatment OptionsThere are limited treatment options in chronic spontaneous urticaria and even fewer in chronic inducible urticaria, positioning Celldex favorably.
Market CompetitionBarzo's ability to provide deep, durable, and safe responses across various patient populations helps differentiate it in an increasingly crowded space, adding to its potential market value.
Celldex News
CLDX FAQ
What was Celldex Therapeutics’s price range in the past 12 months?
Celldex Therapeutics lowest stock price was $14.40 and its highest was $29.38 in the past 12 months.
What is Celldex Therapeutics’s market cap?
Celldex Therapeutics’s market cap is $1.76B.
When is Celldex Therapeutics’s upcoming earnings report date?
Celldex Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 17 days.
How were Celldex Therapeutics’s earnings last quarter?
Celldex Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.856 by $0.006.
Is Celldex Therapeutics overvalued?
According to Wall Street analysts Celldex Therapeutics’s price is currently Undervalued.
Does Celldex Therapeutics pay dividends?
Celldex Therapeutics does not currently pay dividends.
What is Celldex Therapeutics’s EPS estimate?
Celldex Therapeutics’s EPS estimate is -0.9.
How many shares outstanding does Celldex Therapeutics have?
Celldex Therapeutics has 66,406,550 shares outstanding.
What happened to Celldex Therapeutics’s price movement after its last earnings report?
Celldex Therapeutics reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.856. Following the earnings report the stock price went down -2.593%.
Which hedge fund is a major shareholder of Celldex Therapeutics?
Currently, no hedge funds are holding shares in CLDX
Celldex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.33 (83.86% Upside)
$49.33 (83.86% Upside)
Blogger Sentiment
Bullish
CLDX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 680.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.9%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.64%
12-Months-Change
Fundamentals
Return on Equity
-27.17%
Trailing 12-Months
Asset Growth
-18.12%
Trailing 12-Months
Company Description
Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
CLDX Stock 12 Month Forecast
Average Price Target
$49.33
▲(83.86% Upside)
Technical Analysis
Travere Therapeutics
―
Viridian Therapeutics
―
89bio
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Ownership Overview
0.29% Insiders
28.32% Mutual Funds
0.32% Other Institutional Investors
58.23% Public Companies and Individual Investors